Effects of deucravacitinib: A Synthesis of Findings from 17 Studies

  1. Home
  2. Effects of deucravacitinib
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of deucravacitinib: A Synthesis of Findings from 17 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of deucravacitinib: A Synthesis of Findings from 17 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Deucravacitinib is a promising new oral treatment for plaque psoriasis. 8 , 13 Studies have shown that deucravacitinib can improve psoriasis symptoms and is more effective than placebo or other treatments like apremilast. 1 Deucravacitinib targets the interleukin (IL)-23/IL-17 axis, which is considered the main cause of psoriasis. 1 It has also been shown to be safer than other JAK inhibitors with fewer off-target effects. 1 In addition to improving psoriasis symptoms, deucravacitinib has been shown to improve the quality of life for patients. 9

Benefits and Risks

Benefit Summary

Deucravacitinib has been shown to improve psoriasis symptoms and potentially improve the quality of life for patients. 1 It is also safer than other JAK inhibitors with fewer off-target effects. 1 Deucravacitinib is an oral medication, making it easier for patients to take and potentially improving adherence to treatment. 10

Risk Summary

Deucravacitinib has been shown to be safer than other JAK inhibitors with fewer off-target effects. 1 However, deucravacitinib may increase the risk of infection and other side effects. 16 It is important to discuss your risks and benefits with your doctor before starting deucravacitinib. 16

Study Comparison

Commonalities Between Studies

Multiple studies have shown that deucravacitinib is effective for treating plaque psoriasis. 8 , 13 These studies have shown that deucravacitinib can improve psoriasis symptoms and is more effective than placebo or other treatments like apremilast. 1 Deucravacitinib has also been shown to be safer than other JAK inhibitors with fewer off-target effects. 1

Differences Between Studies

Some studies used different dosages and treatment durations for deucravacitinib. 1 The patient populations included in the studies also varied. 16 When comparing and interpreting these findings, it is essential to consider the differences in study design and patient populations. 6

Consistency and Contradictions in Findings

Many studies have shown that deucravacitinib is effective for treating plaque psoriasis. 8 , 13 , 1 However, some studies have shown different results regarding the safety and efficacy of deucravacitinib. 16 Further research is needed to resolve these contradictions. 12

Important Notes for Real-Life Application

While deucravacitinib may be effective for treating plaque psoriasis, it is essential to consult with your doctor before taking it. 9 Deucravacitinib may not be effective for everyone, and there is a risk of side effects. 12 It is important to understand your risks and benefits before taking deucravacitinib. 2

Limitations of Current Research

Research on deucravacitinib is still in its early stages, and more research is needed. 1 In particular, there is not enough data yet on the long-term safety and efficacy of deucravacitinib. 16 Additionally, more research is needed to compare deucravacitinib to other treatments. 6

Future Research Directions

Further research is needed to assess the long-term safety and efficacy of deucravacitinib. 16 Additionally, research is needed to compare the effectiveness of deucravacitinib to other treatments. 6 Further research is also needed to determine if deucravacitinib is effective for treating diseases other than plaque psoriasis. 5

Conclusion

Deucravacitinib is a promising new oral treatment for plaque psoriasis. 8 , 13 Deucravacitinib is safer than other JAK inhibitors with fewer off-target effects. 1 However, it is not effective for everyone and there is a risk of side effects. 12 It is essential to talk to your doctor before taking deucravacitinib to understand your risks and benefits. 9

Literature analysis of 17 papers
Positive Content
17
Neutral Content
0
Negative Content
0
Article Type
2
3
2
8
17
1.

Deucravacitinib for the Treatment of Psoriatic Disease.

Author: LéAna Maria, PuigLuis, TorresTiago

Psoriasis treatment
Reduced itch
Laboratory abnormalities
Serious infections
Thromboembolic events

Deucravacitinib is a new drug that treats psoriasis. It blocks a protein called TYK2, which is involved in the immune response. Deucravacitinib has been shown to be effective and safe in clinical trials.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

2.

The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.

Author: ZhangL, GuoL, WangL, JiangX

Improve psoriasis
Reduce inflammation

This network meta-analysis compares the efficacy and safety of various Janus kinase (JAK) inhibitors for plaque psoriasis. Among the JAK inhibitors, tofacitinib emerged as the most effective and safe option based on PASI75 and PGA responses and incidence of adverse events.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

3.

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.

Author: PappKim, GordonKenneth, ThaçiDiamant, MoritaAkimichi, GooderhamMelinda, FoleyPeter, GirgisIhab G, KunduSudeep, BanerjeeSubhashis

Improved psoriasis clearance
Malignant melanoma
Serious adverse events

Selective inhibition of TYK2 with BMS-986165 at doses of 3 mg daily and higher resulted in greater clearing of psoriasis than placebo.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.

Author: WrobleskiStephen T, MoslinRyan, LinShuqun, ZhangYanlei, SpergelSteven, KempsonJames, TokarskiJohn S, StrnadJoann, Zupa-FernandezAdriana, ChengLihong, ShusterDavid, GilloolyKathleen, YangXiaoxia, HeimrichElizabeth, McIntyreKim W, ChaudhryCharu, KhanJaved, RuzanovMax, TredupJeffrey, MulliganDawn, XieDianlin, SunHuadong, HuangChristine, D'ArienzoCelia, AranibarNelly, ChineyManoj, ChimalakondaAnjaneya, PittsWilliam J, LombardoLouis, CarterPercy H, BurkeJames R, WeinsteinDavid S

Effective in autoimmune diseases
High TYK2 selectivity

This article discusses the development of BMS-986165, a highly selective and potent allosteric inhibitor of TYK2, a member of the JAK family of kinases. Targeting the TYK2 pseudokinase (JH2) domain led to a compound with unprecedented JAK isoform and kinome selectivity, excellent pharmacokinetic properties, minimal profiling liabilities, and efficacy in several murine models of autoimmune disease. This compound has been advanced as the first pseudokinase-directed therapeutic in clinical development for autoimmune diseases.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far.

Author: MartinsAna, LéAna Maria, TorresTiago

PsA treatment

This article reviews the current knowledge on deucravacitinib, a new oral small molecule that selectively inhibits tyrosine kinase 2 (TYK2), for the treatment of PsA. TYK2 is responsible for mediating intracellular signalling of cytokines involved in the pathogenesis of PsA and psoriasis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis.

Author: XuYuanyuan, LiZhixuan, WuShuwei, GuoLinghong, JiangXian

Improved psoriasis symptoms
Adverse events

Oral tyrosine kinase 2 (TYK2) inhibitors demonstrated superior efficacy compared to apremilast in treating moderate-to-severe plaque psoriasis. Deucravacitinib at certain doses showed higher PASI and PGA response rates than placebo and apremilast.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.

Author: ChimalakondaAnjaneya, BurkeJames, ChengLihong, CatlettIan, TagenMichael, ZhaoQihong, PatelAditya, ShenJun, GirgisIhab G, BanerjeeSubhashis, ThroupJohn

Psoriasis
TYK2 inhibition

Deucravacitinib, a TYK2 inhibitor, shows high selectivity for TYK2 compared to JAK 1/2/3 inhibitors, demonstrating its potential as a safe and effective treatment for psoriasis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

8.

Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary.

Author: ArmstrongApril W, GooderhamMelinda, WarrenRichard B, PappKim A, StroberBruce, ThaçiDiamant, MoritaAkimichi, SzepietowskiJacek C, ImafukuShinichi, ColstonElizabeth, ThroupJohn, KunduSudeep, SchoenfeldSteve, LinaberryMisti, BanerjeeSubhashis, BlauveltAndrew

Psoriasis treatment

Deucravacitinib is a new treatment for plaque psoriasis, a skin condition that causes round or oval raised patches (called plaques) typically covered by scales. This can cause itching, cracking, and bleeding, making it difficult to perform basic tasks. While treatments are available, some are ineffective, inconvenient, or have side effects. Researchers are looking for new treatments that are more effective, convenient, and safe.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Deucravacitinib in the treatment of psoriasis.

Author: EstevinhoTomás, LéAna Maria, TorresTiago

Psoriasis treatment
Off-target effects

This article reviews the current knowledge on deucravacitinib, a new oral drug that selectively inhibits tyrosine kinase 2 (TYK2), for the treatment of psoriasis. Deucravacitinib is considered to have a low risk of off-target effects due to its selective TYK2 inhibition.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

13.

Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.

Author: StroberBruce, ThaçiDiamant, SofenHoward, KircikLeon, GordonKenneth B, FoleyPeter, RichPhoebe, PaulCarle, BagelJerry, ColstonElizabeth, ThroupJohn, KunduSudeep, SekaranChitra, LinaberryMisti, BanerjeeSubhashis, PappKim A

Psoriasis treatment

POETYK PSO-2 is a study investigating a new treatment for plaque psoriasis. Plaque psoriasis causes dry, discolored patches of skin that can be flaky and covered in scales. This can cause itching, cracking, and bleeding, making basic tasks difficult. Researchers are looking for new treatments that are more effective, convenient, and have fewer side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.

Author: CatlettIan M, HuYanhua, GaoLu, BanerjeeSubhashis, GordonKenneth, KruegerJames G

Psoriasis treatment
Reduced IL-23 signaling
Reduced type I IFN signaling

Deucravacitinib, a TYK2 inhibitor, blocks IL-23, IL-12, and type I IFN signaling, suggesting potential effectiveness in treating psoriasis. Further clinical trials are needed to confirm its efficacy and safety.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

15.

Progress on the Pharmacological Targeting of Janus Pseudokinases.

Author: HenrySean P, JorgensenWilliam L

Modulates JAKs
Adverse effects

This review discusses the therapeutic potential of targeting Janus kinase (JAK) pseudokinase domains (JH2) for modulating JAK activity without the adverse effects associated with targeting the adjacent kinase domain (JH1). The recent approval of deucravacitinib, a TYK2 JH2 ligand, for plaque psoriasis, demonstrates the potential of this strategy. The structure and targetability of JAK pseudokinases are explored, along with the development of ligands that bind to these domains.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.

Author: YangFan, LuChaofan, WangYanhong, LiuHuilan, LengXiaomei, ZengXiaofeng

Jakinib efficacy
PsA treatment
Psoriasis treatment
Infection risk
Jakinib AE

This systematic review and meta-analysis evaluated the efficacy and safety of Janus kinase (JAK) inhibitors in treating psoriasis and psoriatic arthritis. The study found that all JAK inhibitors demonstrated significantly higher response rates compared to placebo but were associated with an increased risk of adverse events, particularly infections. The study concluded that JAK inhibitors are effective treatments but require further evaluation of long-term efficacy and safety.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.